PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Emergent BioSolutions, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Emergent BioSolutions Co-Hosts Biopreparedness Conference with the French High Committee for Civil Defense - Emergent BioSolutions, Inc. is co-hosting
Emergent BioSolutions Co-Hosts Biopreparedness Conference with the French High Committee for Civil Defense

 

NewswireToday - /newswire/ - Rockville, MD, United States, 2011/09/08 - Emergent BioSolutions, Inc. is co-hosting "Anthrax: Threat and Response," a conference organized by the French High Committee for Civil Defense to discuss anthrax preparedness and response - EBSI.com. NYSE: EBS

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The conference, which brings together military and civilian representatives involved in biological threat management in France, features topics on research programs, threat detection, hospital and medical chain preparedness, anthrax prevention through vaccination, decontamination of critical infrastructure, and global response strategies.

"This is a very important conference, where France's experts discuss the issues and challenges of a terrorist anthrax attack," said Dr. Nigel Lightfoot CBE, former Director of the Health Protection Agency, U.K. and Chair Advisor, Global Health Security Initiative, U.K. Department of Health. "They have shared their preparedness measures thus far and the research that supports their capability development. Other groups who are working towards anthrax preparedness could benefit from some of this research. It was also mentioned that France has made progress in its vaccine development utilizing protective antigen and killed spores, but it is years away from licensure. They recognize, and I strongly believe, that stockpiling of anthrax vaccines, as practiced by the U.S. and the U.K., is an essential component of the response."

"Emergent is pleased to co-host this conference as part of our efforts to raise global awareness of biopreparedness," said Allen Shofe, Senior Vice President Corporate Affairs, Emergent BioSolutions. "In this dialogue and sharing of best practices, we hope to leverage our company's extensive experience in the development, manufacture, and delivery of medical countermeasures that are a critical component of the U.S. government's biodefense strategy for national security."

"We have organized this conference on the anthrax threat and response that gathers experts in the field from France, the United States, and United Kingdom, to discuss the anthrax threat status and the response cycle ranging from detection to medical countermeasures and decontamination," said Christian Sommade, Managing Director of the French High Committee for Civil Defense. "We thank our public and private sponsors for their support."

Attendees include researchers, physicians, first responders, and high level officials in charge of procurement and deployment of detection, medical countermeasures, and decontamination initiatives. Representatives of the European Commission and the U.K. government have equally been involved in this unique exchange of experiences and best practices from France, the U.S. and the U.K.

The French High Committee for Civil Defense is an international non-profit organization composed of State Assemblies, community leaders, and other stakeholders focused on issues related to national security. It works to provide better protection of the French population and businesses, and enhanced resilience of the nation against major risks and threats. The conference is being held today in Paris, France.

About Emergent BioSolutions, Inc.
Emergent BioSolutions (emergentbiosolutions.com) protects and enhances life by developing and manufacturing vaccines and therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. Emergent's marketed and investigational products target infectious diseases, oncology, and autoimmune disorders.

Investors Contact:
Emergent BioSolutions
Robert G. Burrows, Vice President, Investor Relations
P: 301-795-1877 / E: BurrowsR[.]ebsi.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Emergent BioSolutions, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Emergent BioSolutions Co-Hosts Biopreparedness Conference with the French High Committee for Civil Defense

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Tracey Schmitt - EBSI.com 
301-795-1800 SchmittT[.]ebsi.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Emergent BioSolutions, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Emergent BioSolutions, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)